

Gentamicin / Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
4.2	09.04.2021	1841297-00009	Date of first issue: 19.07.2017

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Gentamicin / Betamethasone Ointment Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.
30 Hudson Street, 33rd floor
07302 Jersey City, New Jersey, U.S.A

Telephone : 551-430-6000

E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

1.4 Emergency telephone number

215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1B	H360D: May damage the unborn child.
Specific target organ toxicity - repeated exposure, Category 1	H372: Causes damage to organs through prolonged or repeated exposure.
Long-term (chronic) aquatic hazard, Category 1	H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :  

Signal word : Danger

Hazard statements : H360D May damage the unborn child.
H372 Causes damage to organs through prolonged or repeated exposure.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**

Gentamicin / Betamethasone Ointment Formulation

Version 4.2	Revision Date: 09.04.2021	SDS Number: 1841297-00009	Date of last issue: 10.10.2020 Date of first issue: 19.07.2017
----------------	------------------------------	------------------------------	---

P201 Obtain special instructions before use.
 P264 Wash skin thoroughly after handling.
 P273 Avoid release to the environment.
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.
 P391 Collect spillage.

Hazardous components which must be listed on the label:
 betamethasone

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients**3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Paraffin oil	8012-95-1 232-384-2	Asp. Tox. 1; H304 Aquatic Chronic 4; H413	5
Gentamicin	1403-66-3 215-765-8	Repr. 1A; H360D STOT RE 1; H372 (Kidney, inner ear) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 100 M-Factor (Chronic aquatic toxicity): 1	0,1
betamethasone	378-44-9 206-825-4	Acute Tox. 2; H330 Repr. 1B; H360D STOT RE 1; H372 (Pituitary gland, Immune system, muscle, thymus gland, Blood, Ad- renal gland) Aquatic Chronic 1;	0,064

Gentamicin / Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
4.2	09.04.2021	1841297-00009	Date of first issue: 19.07.2017

		H410	
		M-Factor (Chronic aquatic toxicity): 1.000	

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

- Risks : May damage the unborn child.
Causes damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

- Suitable extinguishing media : Water spray

Gentamicin / Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
4.2	09.04.2021	1841297-00009	Date of first issue: 19.07.2017

Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Gentamicin / Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
4.2	09.04.2021	1841297-00009	Date of first issue: 19.07.2017

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

- | | | |
|-------------------------|---|--|
| Technical measures | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | : | Do not get on skin or clothing.
Do not breathe dust, fume, gas, mist, vapours or spray.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

7.2 Conditions for safe storage, including any incompatibilities

- | | | |
|---|---|---|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations. |
| Advice on common storage | : | Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases |

7.3 Specific end use(s)

- | | | |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|
-

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Gentamicin / Betamethasone Ointment Formulation

Version 4.2 Revision Date: 09.04.2021 SDS Number: 1841297-00009 Date of last issue: 10.10.2020
Date of first issue: 19.07.2017

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Gentamicin	1403-66-3	TWA	0.1 mg/m ³ (OEB 2)	Internal
betamethasone	378-44-9	TWA	1 µg/m ³ (OEB 4)	Internal
Further information: Skin				
		Wipe limit	10 µg/100 cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
Paraffin oil	Workers	Inhalation	Long-term systemic effects	5 mg/m ³
	Workers	Inhalation	Short-term exposure	5 mg/m ³
	Workers	Inhalation	Long-term local effects	5 mg/m ³
	Workers	Inhalation	Acute local effects	5 mg/m ³

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Petrolatum	Oral (Secondary Poisoning)	9,33 mg/kg food

8.2 Exposure controls

Engineering measures

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

Personal protective equipment

- Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the rec-

Gentamicin / Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
4.2	09.04.2021	1841297-00009	Date of first issue: 19.07.2017

Filter type	: Recommended guidelines, use respiratory protection.
	: Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance	: ointment
Colour	: No data available
Odour	: No data available
Odour Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not classified as a flammability hazard
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: No data available
Relative vapour density	: No data available
Relative density	: No data available
Density	: No data available
Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n-octanol/water	: No data available
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, kinematic	: No data available
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.

Gentamicin / Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
4.2	09.04.2021	1841297-00009	Date of first issue: 19.07.2017

9.2 Other information

Flammability (liquids)	:	No data available
Molecular weight	:	No data available
Particle size	:	No data available

SECTION 10: Stability and reactivity**10.1 Reactivity**

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information**11.1 Information on toxicological effects**

Information on likely routes of exposure : Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Paraffin oil:**

Acute oral toxicity	:	LD50 (Rat): > 5.000 mg/kg
Acute dermal toxicity	:	LD50 (Rabbit): > 2.000 mg/kg Assessment: The substance or mixture has no acute dermal toxicity

Gentamicin:

Acute oral toxicity	:	LD50 (Rat): 8.000 - 10.000 mg/kg
---------------------	---	----------------------------------

SAFETY DATA SHEET



Gentamicin / Betamethasone Ointment Formulation



Version 4.2 Revision Date: 09.04.2021 SDS Number: 1841297-00009 Date of last issue: 10.10.2020
Date of first issue: 19.07.2017

LD50 (Mouse): 10.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 0,2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : LD50 (Rat): 67 - 96 mg/kg
Application Route: Intravenous

LD50 (Rat): 371 - 384 mg/kg
Application Route: Intramuscular

LDLo (Monkey): 30 mg/kg
Application Route: Intravenous

betamethasone:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

LD50 (Mouse): > 4.500 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0,4 mg/l
Exposure time: 4 h

Skin corrosion/irritation

Not classified based on available information.

Components:

Paraffin oil:

Species : Rabbit
Result : No skin irritation

Gentamicin:

Species : Rabbit
Result : Mild skin irritation

betamethasone:

Species : Rabbit
Result : Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Paraffin oil:

Species : Rabbit
Result : No eye irritation

Gentamicin / Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
4.2	09.04.2021	1841297-00009	Date of first issue: 19.07.2017

Gentamicin:

Species : Rabbit
Result : Mild eye irritation

betamethasone:

Species : Rabbit
Result : No eye irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Gentamicin:**

Remarks : No data available

betamethasone:

Exposure routes : Dermal
Species : Guinea pig
Result : Weak sensitizer

Germ cell mutagenicity

Not classified based on available information.

Components:**Gentamicin:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: Chromosome aberration test in vitro
Result: equivocal

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intravenous injection
Result: negative

betamethasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Gentamicin / Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
4.2	09.04.2021	1841297-00009	Date of first issue: 19.07.2017

- Test Type: Chromosome aberration test in vitro
Result: positive
- Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Oral
Result: equivocal
- Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:

Gentamicin:

- Carcinogenicity - Assessment : No data available

Reproductive toxicity

May damage the unborn child.

Components:

Gentamicin:

- Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Fertility: NOAEL: 20 mg/kg body weight
Result: No significant adverse effects were reported
- Effects on foetal development : Test Type: Embryo-foetal development
Species: Rabbit
Developmental Toxicity: NOAEL: 3,6 mg/kg body weight
Result: No embryo-foetal toxicity
- Test Type: Embryo-foetal development
Species: Rat
Application Route: Intraperitoneal
Developmental Toxicity: LOAEL: 75 mg/kg body weight
Result: Embryo-foetal toxicity
- Test Type: Embryo-foetal development
Species: Mouse
Application Route: Intraperitoneal
Developmental Toxicity: LOAEL: 10 mg/kg body weight
Result: foetal mortality, No malformations were observed.
- Test Type: Embryo-foetal development
Species: Rat
Application Route: Intraperitoneal
Developmental Toxicity: LOAEL: 50 mg/kg body weight
Result: foetal mortality, No malformations were observed.

Gentamicin / Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
4.2	09.04.2021	1841297-00009	Date of first issue: 19.07.2017

Reproductive toxicity - Assessment : Positive evidence of adverse effects on development from human epidemiological studies.

betamethasone:

Effects on foetal development : Species: Rabbit
Application Route: Intramuscular
Developmental Toxicity: LOAEL: 0,05 mg/kg body weight
Result: Fetotoxicity, Malformations were observed.

Species: Rat
Application Route: Subcutaneous
Developmental Toxicity: LOAEL: 0,42 mg/kg body weight
Result: Malformations were observed.

Species: Mouse
Application Route: Intramuscular
Developmental Toxicity: LOAEL: 1 mg/kg body weight
Result: Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

Components:

Gentamicin:

Target Organs : Kidney, inner ear
Assessment : Causes damage to organs through prolonged or repeated exposure.

betamethasone:

Target Organs : Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Paraffin oil:

Species : Rat, female
LOAEL : 161 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Gentamicin / Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
4.2	09.04.2021	1841297-00009	Date of first issue: 19.07.2017

Gentamicin:

Species : Dog
 LOAEL : 3 mg/kg
 Application Route : Intramuscular
 Exposure time : 12 Months
 Target Organs : Kidney
 Symptoms : Vomiting, Salivation

Species : Monkey
 LOAEL : 50 mg/kg
 Application Route : Subcutaneous
 Exposure time : 3 Weeks
 Target Organs : Kidney, inner ear

Species : Monkey
 LOAEL : 6 mg/kg
 Application Route : Intramuscular
 Exposure time : 3 Weeks
 Target Organs : Blood, Kidney, inner ear, Liver

Species : Rat
 NOAEL : 5 mg/kg
 LOAEL : 10 mg/kg
 Application Route : Intramuscular
 Exposure time : 52 Weeks
 Target Organs : Kidney, Blood

Species : Rat
 NOAEL : 12,5 mg/kg
 LOAEL : 50 mg/kg
 Application Route : Intramuscular
 Exposure time : 13 Weeks
 Target Organs : Kidney

betamethasone:

Species : Rabbit
 LOAEL : 0.05 %
 Application Route : Skin contact
 Exposure time : 10 - 30 d
 Target Organs : Pituitary gland, Immune system, muscle

Species : Rat
 LOAEL : 0.05 %
 Application Route : Skin contact
 Exposure time : 8 Weeks
 Target Organs : thymus gland

Species : Mouse
 LOAEL : 0.1 %
 Application Route : Skin contact
 Exposure time : 8 Weeks
 Target Organs : thymus gland

Gentamicin / Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
4.2	09.04.2021	1841297-00009	Date of first issue: 19.07.2017

Species	:	Dog
LOAEL	:	0,05 mg/kg
Application Route	:	Oral
Exposure time	:	28 d
Target Organs	:	Blood, thymus gland, Adrenal gland

Aspiration toxicity

Not classified based on available information.

Components:

Paraffin oil:

The substance or mixture is known to cause human aspiration toxicity hazards or has to be regarded as if it causes a human aspiration toxicity hazard.

Experience with human exposure

Components:

Gentamicin:

Ingestion	:	Target Organs: Kidney Target Organs: inner ear Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal deafness
-----------	---	---

betamethasone:

Inhalation	:	Target Organs: Adrenal gland
Skin contact	:	Symptoms: Redness, pruritis, Irritation

SECTION 12: Ecological information

12.1 Toxicity

Components:

Paraffin oil:

Toxicity to fish	:	LL50 (Scophthalmus maximus (turbot)): > 100 mg/l Exposure time: 96 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EL50 (Acartia tonsa): > 100 mg/l Exposure time: 48 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
Toxicity to algae/aquatic plants	:	EL50 (Skeletonema costatum (marine diatom)): > 100 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
		NOELR (Skeletonema costatum (marine diatom)): > 1 mg/l Exposure time: 72 h

Gentamicin / Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
4.2	09.04.2021	1841297-00009	Date of first issue: 19.07.2017

Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Gentamicin:

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 86 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

LC50 (Americamysis): 30 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 10 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 1,5 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 (Anabaena flos-aquae (cyanobacterium)): 4,7 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 1,6 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 100

Toxicity to microorganisms : EC50 : 288,7 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

M-Factor (Chronic aquatic toxicity) : 1

betamethasone:

Toxicity to daphnia and other aquatic invertebrates : EC50 (Americamysis): > 50 mg/l
Exposure time: 96 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 34 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 34 mg/l
Exposure time: 72 h

Gentamicin / Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
4.2	09.04.2021	1841297-00009	Date of first issue: 19.07.2017

Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity) : NOEC: 0,052 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

NOEC: 0,07 µg/l
Exposure time: 219 d
Species: Oryzias latipes (Japanese medaka)
Method: OECD Test Guideline 229

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 8 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity) : 1.000

12.2 Persistence and degradability

Components:

Gentamicin:

Biodegradability : Result: rapidly degradable
Biodegradation: 100 %
Exposure time: 28 d
Method: OECD Test Guideline 314

12.3 Bioaccumulative potential

Components:

Paraffin oil:

Partition coefficient: n-octanol/water : log Pow: > 4
Remarks: Calculation

Gentamicin:

Partition coefficient: n-octanol/water : log Pow: < -2

betamethasone:

Partition coefficient: n-octanol/water : log Pow: 2,11

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

Gentamicin / Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
4.2	09.04.2021	1841297-00009	Date of first issue: 19.07.2017

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects

Product:

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN : UN 3077

ADR : UN 3077

RID : UN 3077

IMDG : UN 3077

IATA : UN 3077

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(betamethasone, Gentamicin)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(betamethasone, Gentamicin)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(betamethasone, Gentamicin)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.

Gentamicin / Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
4.2	09.04.2021	1841297-00009	Date of first issue: 19.07.2017

(betamethasone, Gentamicin)

IATA : Environmentally hazardous substance, solid, n.o.s.
(betamethasone, Gentamicin)

14.3 Transport hazard class(es)

ADN : 9
ADR : 9
RID : 9
IMDG : 9
IATA : 9

14.4 Packing group

ADN
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

ADR
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

IMDG
Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)
Packing instruction (cargo aircraft) : 956
Packing instruction (LQ) : Y956
Packing group : III
Labels : Miscellaneous

IATA (Passenger)
Packing instruction (passenger aircraft) : 956
Packing instruction (LQ) : Y956
Packing group : III
Labels : Miscellaneous

14.5 Environmental hazards

ADN
Environmentally hazardous : yes

Gentamicin / Betamethasone Ointment Formulation

Version 4.2	Revision Date: 09.04.2021	SDS Number: 1841297-00009	Date of last issue: 10.10.2020 Date of first issue: 19.07.2017
----------------	------------------------------	------------------------------	---

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H304 : May be fatal if swallowed and enters airways.

H330 : Fatal if inhaled.

H360D : May damage the unborn child.

H372 : Causes damage to organs through prolonged or repeated exposure.

H372 : Causes damage to organs through prolonged or repeated exposure if swallowed.

H400 : Very toxic to aquatic life.

Gentamicin / Betamethasone Ointment Formulation

Version 4.2	Revision Date: 09.04.2021	SDS Number: 1841297-00009	Date of last issue: 10.10.2020 Date of first issue: 19.07.2017
----------------	------------------------------	------------------------------	---

H410 : Very toxic to aquatic life with long lasting effects.
H413 : May cause long lasting harmful effects to aquatic life.

Full text of other abbreviations

Acute Tox. : Acute toxicity
Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard
Asp. Tox. : Aspiration hazard
Repr. : Reproductive toxicity
STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Repr. 1B H360D
STOT RE 1 H372

Classification procedure:

Calculation method
Calculation method

SAFETY DATA SHEET



Gentamicin / Betamethasone Ointment Formulation



Version 4.2	Revision Date: 09.04.2021	SDS Number: 1841297-00009	Date of last issue: 10.10.2020 Date of first issue: 19.07.2017
----------------	------------------------------	------------------------------	---

Aquatic Chronic 1

H410

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN